FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Secondary Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Total-Body Irradiation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2011-02-21

Last Posted Date: 2019-12-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01300572

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Clofarabine
Drug: Cyclosporine
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Total-Body Irradiation

First Posted Date: 2010-12-03

Last Posted Date: 2020-04-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 44

Registration Number: NCT01252667

Locations: 🇺🇸
Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 1 locations

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Phase 2

Completed

Conditions: Adult Acute Lymphoblastic Leukemia
Adult Acute Myeloid Leukemia
Adult Diffuse Large B-Cell Lymphoma
Adult Myelodysplastic Syndrome
Adult Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma
Childhood Acute Lymphoblastic Leukemia
Childhood Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia in Remission

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Sirolimus
Radiation: Total-Body Irradiation

First Posted Date: 2010-12-02

Last Posted Date: 2019-12-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 77

Registration Number: NCT01251575

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 2 locations

Vitamin D, Diet and Activity Study

Not Applicable

Completed

Conditions: Breast Cancer
Obesity
Hypovitaminosis D

Interventions: Dietary Supplement: Vitamin D
Dietary Supplement: Placebo

First Posted Date: 2010-11-15

Last Posted Date: 2013-08-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 218

Registration Number: NCT01240213

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant

Not Applicable

Completed

Conditions: Hyperglycemia
Malignant Neoplasm

Interventions: Other: computer-assisted intervention

First Posted Date: 2010-11-09

Last Posted Date: 2015-04-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01236885

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy

Phase 2

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Previously Treated Myelodysplastic Syndromes
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Procedure: standard follow-up care
Other: medical chart review
Procedure: quality-of-life assessment

First Posted Date: 2010-11-05

Last Posted Date: 2020-07-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 200

Registration Number: NCT01235572

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase 3

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Myelodysplastic Syndrome
Recurrent Plasma Cell Myeloma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Refractory Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Aggressive Non-Hodgkin Lymphoma
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Small Lymphocytic Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Drug: Sirolimus

First Posted Date: 2010-11-01

Last Posted Date: 2019-10-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 174

Registration Number: NCT01231412

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 8 locations

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Completed

Conditions: Bronchiolitis Obliterans
Cutaneous Sclerosis
Graft vs Host Disease

First Posted Date: 2010-09-21

Last Posted Date: 2016-10-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 911

Registration Number: NCT01206309

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 11 locations

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

Not Applicable

Completed

Conditions: Menopause
Hot Flashes
Vasomotor Symptoms

Interventions: Dietary Supplement: Placebo
Behavioral: Yoga
Dietary Supplement: Omega-3
Behavioral: Exercise
Behavioral: Usual Activity

First Posted Date: 2010-08-10

Last Posted Date: 2014-08-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 355

Registration Number: NCT01178892

Locations: 🇺🇸
Kaiser Division of Research, Oakland, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Group Health Research Institute, Seattle, Washington, United States

WebQuit Online Smoking Cessation Study

Phase 1

Completed

Conditions: Smoking

Interventions: Behavioral: WebQuit study group
Behavioral: WebQuit control group

First Posted Date: 2010-07-21

Last Posted Date: 2013-10-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 721

Registration Number: NCT01166334

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy